

## Special Issue

# Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease

### Message from the Guest Editor

Extensive studies of  $\alpha$ -synuclein function and dysfunction revealed its involvement in multiple normal and aberrant molecular processes and consequently, various effects on the nervous system cell biology. However, certain other types of cells normally express this protein, and they may also be affected by  $\alpha$ -synuclein dysfunction and thus contribute to pathological changes in  $\alpha$ -synucleinopathies. It would be beneficial to summarise scattered data on these aspects of  $\alpha$ -synuclein biology and pathology. Recent studies draw attention to the other two members of the family, b-synuclein and g-synuclein, whose role in homeostasis and pathology is still poorly understood. Three members of the family share many structural properties and have an overlapping pattern of expression and intracellular distribution in the developing and adult nervous system, which point to functional redundancy within the family. However, each synuclein has its own functions unshared with two other synucleins and in some cellular mechanisms and pathways, these functions could be antagonistic rather than synergistic.

---

### Guest Editor

Dr. Natalia Ninkina

School of Biosciences, Cardiff University, Museum Avenue, Cardiff CF10 3AX, UK

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/112542](https://mdpi.com/si/112542)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).